Future-oriented packaging concepts from Sanner

At booth B76, the desiccant specialist will, amongst others, exhibit its drop-in solutions for moisture-sensitive pharmaceuticals. The AdPack® desiccant sachets made of Tyvek® offer an ideal combination of moisture protection, breathability and durability. The desiccant capsules AdCap® combine the advantages of conventional desiccant capsules and canisters. They make sure that moisture or odors are optimally adsorbed right after filling. According to demands, they are available with silica gel, molecular sieves, activated carbon or combinations.

Sanner offers the broadest portfolio of plastic tubes and closures for effervescent tablets worldwide. “Customers receive complete packaging solutions from a single source with optimally compatible components. Moreover, we offer solutions such as in-mold labeling or the user-friendly FOG 27 closure for a differentiated appearance at point of sale,” says Dirk Mähr, CEO of Sanner GmbH.

125 years of packaging expertise

Pharmapack is also the beginning of a number of celebrations for the 125th company anniversary. “We look back on a long company history with pride,” says Dirk Mähr. “But above all, we are looking into the future. Sanner is at the forefront with groundbreaking developments and innovative cooperations.”

This is underlined by medical solutions such as transfer devices or syringe components from the Engineered Packaging Solutions product segment. Apart from the intelligent inhalation systems for true medication adherence in the treatment of respiratory diseases, which Sanner developed together with the digital health start-up Amiko, the company is working on further solutions that enable patients to take their medicine correctly and effectively thanks to digital communication. Corporate Development Manager Christian Schierholz will also present digital solutions for proper treatment adherence as part of the Pharmapack Learning Lab on February 7th, 12.10 pm.

Sanner at Pharmapack: Paris, 6 and 7 February 2019, booth B76

Gerresheimer to expand its services to include irradiation of plastic dropper bottles used in ophthalmology and rhinology

Gerresheimer will use this year’s Pharmapack held in Paris, Porte de Versailles, as a platform to unveil their latest ophthalmology and rhinology services at booth B62. The company has teamed up with select certified partners to add surface finishing of plastic dropper bottles to their irradiation services.

“We want to make life easier for our customers when it comes to procuring their dropper bottles and, by treating our products with gamma radiation, we are adding in an important work step before filling,” says Niels Düring, Global Executive Vice President Plastic Packaging. “To help us in this, we are relying on selected, recognized, and certified partners.” The chosen partner companies have the requisite certification in accordance with ISO standards 11137, 11737, and 13004.

Benefits

The benefits of this service speak for themselves: Gerresheimer is assuming responsibility for handling this work step from start to finish, including transport to the irradiation company, monitoring and inspecting its work, and delivering to the location specified by the customer. The inspection processes also involve physically and chemically testing the product characteristics after irradiation. Gerresheimer regulates the validation and revalidation of the entire process, helping to reduce costs for the customer.

Cleanroom production

Gerresheimer’s range of ophthalmology and rhinology products encompasses bottles and dropper inserts made from low-density polyethylene (LDPE) with pump systems to match. Irradiation also ensures the products are germ-free. As a specialist in plastic packaging for the pharmaceutical industry, Gerresheimer offers a wide range of innovative packaging solutions for solid, liquid, and opthalmological products. All of the company’s primary packaging for the pharmaceutical industry is produced in ISO class 7 and class 8 cleanrooms at its plants in Vaerloese (Denmark) and Boleslawiec (Poland).

Low germ level thanks to ISO-standard irradiation

The population of viable microorganisms on the surface of a product and/or packaging is called the bioburden. The bioburden is determined in accordance with ISO 11737. Raw materials, components, packaging, and medical products are all investigated in order to gather information about the germ composition and level of germ contamination before treatment. A stable bioburden guarantees a successful irradiation process.

Gerresheimer will be at booth B62 of Pharmapack in Paris (Porte de Versailles) from February 6 to 7. The products of Sensile Medical will be presented at booth A94.

Almac Group Flows into Continuous Technology

Almac Sciences, a member of the Almac Group, has expanded its technology capabilities within its Active Pharmaceutical Ingredients (API) services & chemical development portfolio with the implementation of continuous flow expertise at its global headquarters in Craigavon, UK, with further plans to introduce flow capacity within Arran Chemical Company (Athlone, Ireland).

Continuous flow manufacture is an innovative technology platform which is gaining momentum within the pharmaceutical industry with the FDA supporting the adoption for the manufacture of APIs. It offers significant improvements in relation to product quality, process safety, reduction in plant footprint and provides the ability to perform chemistry that is difficult or impossible to do in batch mode.

Almac Sciences has a 4-year strategy to develop Flow Assisted Synthesis Technology (FAST) focusing on four key areas; (1) high pressure hydrogenations, (2) high energy chemistry, (3) oxidation and (4) photo-redox LED mediated chemistries. To support this, Almac Sciences has been awarded a Knowledge Transfer Partnership from Innovate UK for the development of novel routes to chiral amines using flow technology. In addition, Arran Chemical Company, in partnership with Queen’s University, Belfast, has been successful in securing a Horizon 2020 funded programme to support 4 PhD studentships for the next 4 years (beginning in 2019) in line with the FAST strategy.

Almac will develop highly flexible, robust, efficient flow technology platforms for continuous manufacture for the benefit of its clients who seek high quality and best-in-class pharmaceutical synthesis.

Prof. Tom Moody, VP Technology Development & Commercialisation, Almac & Arran Chemical Company commented, “The introduction of continuous flow technology further enhances Almac Sciences’ capabilities within API development and manufacture. Flow technology is highly flexible, robust, economic and regarded as the most exciting and innovative growth technology for the preparation of APIs. We are delighted to now offer this within our portfolio and will strive to continue providing world-class solutions to advance human health globally.”

Merck and Tencent Announce Collaboration on Intelligent Digital Healthcare Services in China

Merck, a leading science and technology company, signed a strategic collaboration agreement today with Tencent, a leading provider of Internet value added services. The collaboration will primarily focus on increasing public disease awareness and providing more accessible healthcare services via digital platforms in China, by leveraging the company’s scientific leadership and expertise combined with Tencent’s leading technology in the fields of internet and artificial intelligence.

“In this collaboration with Tencent, we will jointly explore the innovative combination of patient-centric healthcare management and digital platforms, which brings us one step closer to reaching our mission of transforming the lives of 40 million patients in China by 2025,” said Rogier Janssens, Managing Director and General Manager of Merck’s Biopharma Business in China. “The Healthcare Business of Merck in China is committed to developing a multi-dimensional intelligent medical ecosystem together with more cross-industry partners for the benefit of patients.”

“Tencent launched a major strategic upgrade in 2018. While we continue to stay committed to Consumer-Based Internet, we are also actively embracing Industrial Internet[i], with the healthcare field being an important focus.” Zhang Meng, Vice President of Tencent Medical said, “We want to build on advanced internet platforms and artificial intelligence, big data, and cloud computing capabilities, and work with partners to make healthcare in China more convenient and efficient for all patients.”

With the agreement, Merck and Tencent will create intelligent digital healthcare services, thereby increasing public knowledge of diseases and improving patients’ understanding of disease symptoms and effective treatment options. The collaboration will also provide patients with more convenient and smarter medical services, helping to better manage chronic diseases.

The focus areas will include all treatment areas of Merck’s Healthcare business in China: in allergies, Merck and Tencent will explore digital services that increase the awareness of allergy symptoms and encourage adherence to treatment plans; in the area of infertility, the collaboration will work to enhance awareness of disease and treatment options and help patients who are in need of fertility resources to shorten the process of medical treatment. The two companies will also focus on diabetes, thyroid disorders and cardiovascular diseases, as well as oncology such as metastatic colorectal cancer (mCRC).

In the future, Merck and Tencent will continue to extend the scope of collaboration to other areas such as exploring the use of innovative medical service models based on “A.I. doctors” to provide more comprehensive disease awareness education and treatment services for mCRC and other diseases.

Leveraging the collaboration with Tencent at the beginning of 2019, Merck is driving digitalization, an integral part of Merck’s strategy in China. With big data insights, new platforms and partnerships, Merck will adopt a more integrated approach to contribute to the key goals of the national “Healthy China 2030” blueprint and to safeguard the health of all Chinese citizens.

Abbott To Acquire Cephea Valve Technologies, Inc.

Abbott has announced that it has exercised its option to purchase Cephea Valve Technologies, Inc., a privately held medical device company developing a less-invasive heart valve replacement technology for people with mitral valve disease.

Cephea’s technology is being developed to provide an option for people whose diseased mitral valves need to be replaced. The artificial valve is designed to be delivered through a vein in the leg, forgoing the need for open-heart surgery. Replacement of the diseased mitral valve restores normal blood flow through the heart.

“The acquisition of Cephea builds on Abbott’s strong position in structural heart therapies and is consistent with our strategy to develop comprehensive treatments for people with mitral valve disease,” said Michael Dale, vice president of Abbott’s structural heart business. “Cephea’s novel approach to replace the mitral valve adds to our other catheter-based technologies and is being developed to provide an additional option for patients who suffer from this difficult-to-treat disease.”

Mitral valve disease is the most common heart valve problem, affecting more than 4 million people in the U.S. alone. It comes in two forms: regurgitation, a condition where blood leaks backward into the heart, or, less commonly, stenosis, a narrowing of the valve. The condition puts people at risk for health complications such as irregular heartbeats, high blood pressure, blood clots or heart failure.

Abbott has led the development of minimally invasive solutions for mitral valve disease since 2009 when it acquired Evalve, Inc., with its MitraClip technology. MitraClip, the first-of-its-kind product to repair leaky heart valves, launched in Europe in 2008 and the U.S. in 2013 and remains the only mitral valve repair device of its kind on the market.

In 2015, Abbott expanded its portfolio by acquiring Tendyne Holdings, Inc. and securing an option to acquire Cephea Valve Technologies, companies that are both developing minimally invasive devices intended to fully replace the mitral valve in the heart. Minimally invasive mitral valve procedures are expected to become a multi-billion-dollar market in the coming years. In addition, Abbott acquired St. Jude Medical in 2017, adding to the company’s expertise and offerings to treat structural heart disease.